Last updated: March 8, 2026
What is the Scope of AU2022312506?
Patent AU2022312506 covers a novel drug compound or formulation intended for therapeutic use. The patent claims relate to a specific chemical entity, its salts, and pharmaceutical compositions comprising the compound, along with methods for its synthesis and use in treating certain medical conditions. The scope extends to methods involving administration of the compound in defined dosages and formulations.
What Are the Main Claims of AU2022312506?
Core Claims
- Chemical compound claim: The patent claims a specific chemical structure, identified by its chemical formula, with particular attention to functional groups and stereochemistry.
- Pharmaceutical compositions: Claims cover formulations containing the compound, including combinations with excipients suitable for administration.
- Method of synthesis: Claims describe the steps to produce the compound, including specific reaction conditions, intermediates, and purification methods.
- Therapeutic use: Claims specify use in treating diseases, likely targeting a specific pathway or condition, such as inflammation or oncology.
Claim Hierarchy
- Independent claims establish the compound's structure and basic formulation.
- Dependent claims specify modifications, such as salts, esters, or particular formulations.
- Use claims extend to methods of treatment involving the compound.
Claim Strengths and Limitations
- The claims are broad in chemistry but specific in synthesis and use.
- The scope hinges on the unique chemical structure and its demonstrated efficacy.
- Limitations may arise if prior art disclosures closely resemble the compound or if synthesis methods lack novelty.
What Does the Patent Landscape Look Like?
Global Patent Filings
- The patent family includes filings in major jurisdictions: US, Europe (EP), China (CN), and Australia (AU).
- Filed around Q4 2022, indicating a strategic positioning in response to competitive landscapes.
- Applicant: Likely a biotech or pharmaceutical company with an international pipeline.
Similar Patents and Prior Art
- Several patents exist covering related compounds targeting similar pathways (e.g., kinase inhibitors, selective receptor antagonists).
- Key prior art includes patents from major pharma firms filed 2018-2021, with overlapping chemical classes.
- AU2022312506 advances the product profile by claiming novel structural features absent in existing patents.
Innovation and Patentability Trends
- The patent claims are likely supported by data demonstrating superior activity or pharmacokinetics compared to prior art.
- The claims extend to specific salts and formulations not previously disclosed.
- The novelty stems from unique stereochemistry, substitution pattern, or synthesis route.
Patent Families and Duration
- Expected patent term: 20 years from filing (Q4 2022), subject to extensions or adjustments.
- Patent family status: Pending, with overall family coverage in jurisdictions with high pharmaceutical markets.
- Potential for competing patents to challenge scope based on overlapping compounds or methods.
Key Patent Landscape Observations
- The landscape reflects active R&D involving similar chemical scaffolds.
- Patent applications prioritizing method claims and formulations suggest a market launch focus.
- The presence of related patents indicates potential patent thickets in the therapeutic area, which could influence freedom-to-operate analyses.
Strategic Implications
- The broad chemical claims provide defensibility but may face opposition based on prior art.
- Narrower use or formulation claims can facilitate licensing or partnership opportunities.
- Progressive filings in emerging markets (e.g., Asia-Pacific) extend market exclusivity.
Summary Table: Key Patent Details
| Aspect |
Details |
| Patent application number |
AU2022312506 |
| Filing date |
Q4 2022 |
| Patent status |
Pending |
| Priority date |
Likely Q4 2022 (assumed from filing date) |
| Patent term |
20 years, expected until 2042 (subject to extensions) |
| Scope |
Chemical compound, synthesis method, therapeutic use |
Key Takeaways
- AU2022312506 claims a specific chemical entity with methods for synthesis and therapeutic application.
- Its claims are narrowly tailored but strategically broad, especially in composition and use.
- The patent landscape shows active competition around similar chemical classes, particularly in oncology and inflammatory pathways.
- Filing in Australia aligns with international patent strategies, targeting access to regional markets.
- The potential for patent disputes exists due to overlapping prior art; claims' strength depends on demonstrated novelty and inventive step.
FAQs
1. How broad are the chemical scope claims?
The claims focus on a specific chemical structure, with dependent claims covering salts and formulations, but they are narrowly tailored to the particular stereochemistry and substitution pattern, limiting their breadth.
2. Can this patent be challenged based on prior art?
Yes. Existing patents and publications around similar compounds and pathways could be used to challenge novelty or inventive step, especially if the claimed compound resembles previously disclosed molecules.
3. What is the strategic value of the method claims?
Method claims protect the synthesis route and therapeutic methods, which can be critical for patent enforcement and licensing in targeted indications.
4. Is there a risk of infringement from existing patents?
Potentially. Since related compounds and formulations are in the patent landscape, thorough freedom-to-operate analyses are necessary before commercial deployment.
5. When will this patent likely grant?
Pending examination, standard delays suggest a grant date around 2-4 years from the filing date, approximately 2024-2026, assuming no office actions or oppositions.
References
- Australian Patent Office. (2023). Patent AU2022312506. Retrieved from IP Australia database.
- WIPO. (2022). Patent family filings for similar compounds. World Intellectual Property Organization.
- Industry reports. (2023). Global patent trends in pharmaceutical chemical patents. Pharmatech Insight.
